Etirinotecan Pegol

N/A

Report date: 2025/07/01 20:00:14

Base Information

Drug NameEtirinotecan Pegol
Drug Alias Name培伊替康etirinotecanum pegolumPegylated irinotecan培戈-依诺替康PEG-Irinotecan (Nektar) +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaN/A
Originator CompaniesNektar Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNektar TherapeuticsRoswell Park Cancer InstituteNektar Therapeutics Uk Ltd
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[12] 

Other Information

ATC CodeL01CE03
Related LinksWikipediaKEGG